Charles River Laboratories Interna revenue and financials
$304.96Change from previous close: −1.87%Absolute change: −$5.81
In the fiscal year ended December 2025, Charles River Laboratories Interna reported revenue of $4.02B (−0.85% year over year). The net loss was $144.34M.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- −0.85%
- 2025 vs 2024
- Net margin
- -3.6%
- 2024: 0.5%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 180 | 41.1 | 148 | 214 | 205 | 172 | 159 | 252 | 194 | 130 | 221 | 205 |
| Depreciation and amortization | 65.8 | 67.2 | 125 | 85.2 | 79.8 | 78.7 | 65.0 | 88.2 | 86.1 | 85.4 | 80.5 | 78.9 |
| Capital expenditure | -31.1 | -55.9 | -89.0 | -35.6 | -35.3 | -59.3 | -75.6 | -38.7 | -39.5 | -79.1 | -78.3 | -65.9 |
| Investing cash flow | 28.1 | -408 | -92.8 | -33.7 | -37.3 | -45.5 | -76.1 | -21.3 | -61.9 | -85.8 | -238 | -79.6 |
| Financing cash flow | -165 | 348 | -51.9 | -153 | -227 | -105 | -75.9 | -208 | -286 | 18.3 | 124 | -163 |
| Share repurchases | -116 | -208 | -0.1 | -0.1 | -7.4 | -353 | -0.1 | -101 | -8.9 | -9.4 | -0.1 | -0.0 |
| Debt issued | 353 | 912 | 157 | 107 | 547 | 416 | 105 | 236 | 440 | 301 | 443 | 51.2 |
| Debt repaid | -390 | -356 | -208 | -254 | -738 | -149 | -177 | -330 | -695 | -292 | -321 | -214 |
| Effect of exchange rates | -0.8 | 1.2 | 3.9 | -3.0 | 12.7 | 5.3 | -13.4 | 7.7 | -3.3 | -8.4 | 12.7 | -6.2 |
| Net change in cash | 42.4 | -17.8 | 6.8 | 24.5 | -47.0 | 26.2 | -6.1 | 30.6 | -158 | 54.1 | 119 | -43.2 |
| Free cash flow | 149 | -14.8 | 58.6 | 178 | 169 | 112 | 83.7 | 213 | 154 | 50.7 | 143 | 140 |
| Levered free cash flow | 113 | 78.5 | 98.4 | 132 | 153 | 141 | 46.3 | 223 | 148 | 59.8 | 38.2 | 101 |